This information was published on 2025-10-20T11:28:44 for IP Right Registration Published.
| Field | Value |
| (210) | 2574493 (IR 1868627) |
| (220) |
22 May 2025
|
| (300) |
US, 26 Nov 2024, 98873501
|
| (511) (510) |
Class 1
Biological preparations for laboratory, biopharmaceutical processing, and research purposes, namely, reference standards; biological preparations for cancer research; biological preparations for quality control; cell line-derived reference standards for research purpose; samples for use in biochemical or biological laboratory analysis for research purposes; cell line-derived products for scientific and research purposes, including for clinical investigations and for use in product testing; reference standards used for research purposes, namely, next generation sequencing, droplet-digital, real-time pcr or sanger sequencing. Class 5 Cell line-derived reference standards used in clinical samples; reference standard substances used for clinical tests for medical purposes; reference standards used for next generation sequencing, droplet-digital, real-time pcr or sanger sequencing; reference standards used for detecting chromosomal abnormalities; reference standards used for analysing biological samples. Class 40 Custom manufacture of cell line-delivered products for medical and commercial applications; custom manufacture of reference standards. |
| (540) | MIMIX |
| (550) | Word |
| (730) |
Revvity Health Sciences, Inc.
|
Find out more about publications on the About page.